DXCM Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 10.17% compared to DexCom's net margin of -19.35%. DexCom's return on equity of 24.26% beat iRhythm Technologies's return on equity of -112.03%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 20.48%. On the other hand iRhythm Technologies has an analysts' consensus of $143.83 which suggests that it could fall by -0.77%. Given that DexCom has higher upside potential than iRhythm Technologies, analysts believe DexCom is more attractive than iRhythm Technologies.

DexCom has a beta of 1.458, which suggesting that the stock is 45.846% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.402, suggesting its more volatile than the S&P 500 by 40.168%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than iRhythm Technologies quarterly revenues of $158.7M. DexCom's net income of $105.4M is higher than iRhythm Technologies's net income of -$30.7M. Notably, DexCom's price-to-earnings ratio is 61.07x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.09x versus 7.34x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 10.17% compared to DexCom's net margin of -45.89%. DexCom's return on equity of 24.26% beat Masimo's return on equity of -39.91%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 20.48%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 14.28%. Given that DexCom has higher upside potential than Masimo, analysts believe DexCom is more attractive than Masimo.

DexCom has a beta of 1.458, which suggesting that the stock is 45.846% more volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than Masimo quarterly revenues of $372M. DexCom's net income of $105.4M is higher than Masimo's net income of -$170.7M. Notably, DexCom's price-to-earnings ratio is 61.07x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.09x versus 4.38x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 10.17% compared to DexCom's net margin of 6.22%. DexCom's return on equity of 24.26% beat Insulet's return on equity of 36.9%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 20.48%. On the other hand Insulet has an analysts' consensus of $336.00 which suggests that it could grow by 10.39%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.458, which suggesting that the stock is 45.846% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than Insulet quarterly revenues of $569M. DexCom's net income of $105.4M is higher than Insulet's net income of $35.4M. Notably, DexCom's price-to-earnings ratio is 61.07x while Insulet's PE ratio is 54.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.09x versus 10.24x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 10.17% compared to DexCom's net margin of 28.26%. DexCom's return on equity of 24.26% beat ResMed's return on equity of 25.76%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 20.48%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 5.76%. Given that DexCom has higher upside potential than ResMed, analysts believe DexCom is more attractive than ResMed.

DexCom has a beta of 1.458, which suggesting that the stock is 45.846% more volatile than S&P 500. In comparison ResMed has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.169%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.85% to investors and pays a quarterly dividend of $0.53 per share. DexCom pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DexCom quarterly revenues are $1B, which are smaller than ResMed quarterly revenues of $1.3B. DexCom's net income of $105.4M is lower than ResMed's net income of $365M. Notably, DexCom's price-to-earnings ratio is 61.07x while ResMed's PE ratio is 28.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.09x versus 7.34x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.